who to go to with symptoms of jaundice and scleral icterus

#WHO TO GO TO WITH SYMPTOMS OF JAUNDICE AND SCLERAL ICTERUS FULL#

Early symptoms include malaise, fatigue, loss of appetite, muscle and joint pain. 16.8.3 Management of adverse effects HepatotoxicityĬlinical features resemble that of viral hepatitis.

#WHO TO GO TO WITH SYMPTOMS OF JAUNDICE AND SCLERAL ICTERUS FULL#

If signs and symptoms of active TB develop, the patient should undergo full evaluation ( Chapter 3, Chapter 4 and Chapter 5). Other patients should be tested if they develop symptoms of hepatotoxicity.Īny problems with adherence should be addressed with the patient. An official ATS statement: hepatotoxicity of antituberculosis therapy. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. Baseline LFTs are elevated or LFTs increase during LTBI treatment: monitor LFTs once a week Citation 2.Baseline LFTS are normal: monitor LFTs monthly.

In patients with pre-existing hepatic disease: 16.8.2 Follow-upĪll patients should be evaluated monthly for signs and symptoms of active TB, adverse effects and adherence. patients with HIV infection, women during pregnancy and post-partum period, chronic alcohol consumption, age > 35 years, concomitant use of hepatotoxic drugs, history of hepatic disease). 2020.ĭepending on available resources, baseline LFTs can be performed in groups at risk for hepatotoxicity (e.g. Module 1: prevention - tuberculosis preventive treatment. WHO operational handbook on tuberculosis.

LTBI treatment is contra-indicated in patients with end-stage hepatic disease or LFTs > 5 times the upper limit of normal (ULN) and should be used with caution in patients with LFTs > 3 times ULN Citation 1. The benefit of LTBI treatment should be weighed against the potential risk of aggravation of existing hepatic disease. aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin should be performed. 16.8.1 Baseline assessment of liver functionīefore initiating LTBI treatment, look for clinical signs of hepatic disease and specific risks of hepatotoxicity.įor patients with hepatic disease, baseline liver function tests (LFTs), i.e. For the modality of administration of LTBI treatments see Chapter 13.

Who to go to with symptoms of jaundice and scleral icterus